News | December 16, 2007

FDA Clears Medtronic’s New Insertable Cardiac Monitors

December 17, 2007 - Medtronic Inc. today announced it received FDA clearance of the Reveal DX and Reveal XT, new insertable cardiac monitors (ICMs) designed to provide diagnostic and monitoring insights to cardiologists managing their patients with syncope (fainting) or abnormal heart rhythms, including ventricular tachyarrhythmias (VT), fast ventricular tachyarrhythmias (FVT), bradyarrhythmias and asystole.

The Reveal DX continuously monitors the heart’s electrical activity in order to help physicians diagnose whether or not symptoms such as fainting, dizziness and unexplained seizure-like episodes have a cardiovascular cause. Causes of syncope can be heart rhythm disturbances or abnormalities in the structure of the heart. Syncope can lead to serious injury or can be a precursor to sudden cardiac death. Approximately 1.5 million people worldwide suffer from unexplained syncope. In almost 10 percent of patients, syncope has a cardiac cause; in 50 percent, a non-cardiac cause; and in 40 percent of patients the cause of syncope is unknown, according to a study published in the New England Journal of Medicine (E.S. Soteriades et al. N Eng J Med. 2002; 347 (12):878-885.). It is a leading cause of emergency room visits. Syncope is difficult to diagnose as syncopal episodes are often too infrequent and unpredictable for detection with conventional monitoring techniques.

Placed just under the skin of the chest area using local anesthesia during an outpatient procedure, the Reveal DX monitor records important cardiac rhythm data, which may help a physician to diagnose the patient so the appropriate treatment can be undertaken. The device weighs 15 grams and is approximately the size of a memory stick. Unlike a pacemaker or implantable cardioverter-defibrillator, there are no leads that extend from the device into the heart’s chambers. To store an electrocardiogram (ECG) at the time of an episode, a patient places a hand-held, pager-sized activator over the device and presses a button. Later a physician analyzes the stored information and determines if the episode was caused by an abnormal heart rhythm.

The Reveal DX will be commercially available in the U.S. beginning next week and the Reveal XT will follow.

For more information: www.medtronic.com

Related Content

Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients
News | Heart Failure| July 14, 2017
A review appearing in the July 18 issue of the Journal of the American College of Cardiology (JACC) discusses current...
Biosense webster multielectrode balloon RF ablation catheter

The Biosense Webster multi-electrode balloon RF ablation catheter. Each electrode can have varied power settings to avoid damage to underlying tissues like the esophagus. 

Feature | EP Lab| June 22, 2017 | Dave Fornell
Electrophysiology (EP) technology has been advancing rapidly the past few years with new ablation tools to improve...
Abbott SJM Confirm RX Implantable cardiac monitor gains european CE mark approval
News | May 30, 2017
May 30, 2017 — Abbott recently announced European CE mark and first use of the new Confirm Rx Insertable Cardiac Moni
Medtronic Reveal Linq implantable cardiac monitor

The Medtronic Reveal Linq implantable cardiac monitor is the smallest implantable monitor on the market. It is used as a long-term Holter monitor for 24-hour a day, 365-day a year patient monitoring. The device uses wireless connectivity to download the patient data with a patient bedside base unit to send the information over the internet so it is accessible by physicians.

Feature | Atrial Fibrillation| May 16, 2017
May 16, 2017 - The study using small, subcutaneous implantable cardiac monitors for long-term, 24-hour a day monitori
An electrophysiology EP ablation procedure to treat a heart arrhythmia
Feature | HRS| May 16, 2017
May 16, 2017 — Here is a list of the late-breaking clinical trials presented at the Heart Rhythm Society (HRS) 2017 a
Digital Health Company Murj Announces $4.5 Million in Financing
News | Implantable Cardiac Monitor (ICM)| April 19, 2017
Murj Inc., a digital health company that helps manage implantable cardiac device data, announced more than $4.5 million...
Sponsored Content | Videos | EP Lab| April 10, 2017
A discussion with Heart Rhythm Society (HRS) President Michael Gold, M.D., Ph.D., director of cardiology and associat
Sponsored Content | Videos | ACC| April 03, 2017
DAIC Editor Dave Fornell takes a tour of some of the interesting new technologies from the vendor booths on the expo
Medtronic, Reveal LINQ ICM, insertable cardiac monitor, FDA clearance, TruRhythm Detection
Technology | Implantable Cardiac Monitor (ICM)| March 15, 2017
Medtronic plc announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its Reveal LINQ Insertable Cardiac...
heart monitoring technology, climbers, high altitudes, Circulation study, cardiac diagnostics, Medtronic, Reveal LINQ
News | Implantable Cardiac Monitor (ICM)| March 14, 2017
Climbing above 4,000 meters can provoke abnormal heart rhythms in otherwise healthy mountaineers, with the...
Overlay Init